We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · August 13, 2021

Plasma NfL Has Diagnostic and Prognostic Performance for Alzheimer Disease in Adults With Down Syndrome

The Lancet Neurology


Additional Info

The Lancet Neurology
Diagnostic and Prognostic Performance and Longitudinal Changes in Plasma Neurofilament Light Chain Concentrations in Adults With Down Syndrome: A Cohort Study
Lancet Neurol 2021 Aug 01;20(8)605-614, M Carmona-Iragui, D Alcolea, I Barroeta, L Videla, L Muñoz, KL Van Pelt, FA Schmitt, DD Lightner, LM Koehl, G Jicha, S Sacco, C Mircher, SE Pape, R Hithersay, ICH Clare, AJ Holland, G Nübling, J Levin, SH Zaman, A Strydom, AS Rebillat, E Head, R Blesa, A Lleó, J Fortea

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading